display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
metastatic/advanced RCC (mRCC) - 2nd line (L2)
metastatic/advanced RCC (mRCC) - 2nd line (L2)
immune chekpoint inhibitors
anti-PD-(L)1
atezolizumab based treatment
atezolizumab plus cabozantinib CONTACT-03
nivolumab based treatment
nivolumab alone CheckMate 025

Study type:

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons